Nomifensine in parkinsonism.
Open Access
- 1 December 1976
- journal article
- clinical trial
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 39 (12) , 1219-1221
- https://doi.org/10.1136/jnnp.39.12.1219
Abstract
Nomifensine, a tetrahydroisoquinolone antidepressant which facilitates dopaminergic and noradrenergic transmission, was studied in 28 Parkinsonism patients most of whom were also receiving conventional medications. Double-blind evaluations revealed a moderate therapeutic action at a mean dose level of 150 mg daily. Adverse reactions were encountered, similar to those identical by levodopa.Keywords
This publication has 6 references indexed in Scilit:
- Actions of dopaminergic agonists on motor function.1975
- Nomifensine: A potent dopaminergic agonist of antiparkinson potentialPsychopharmacology, 1975
- Effect of nomifensine (Hoe 984), a new antidepressant, on uptake of noradrenaline and serotonin and on release of noradrenaline in rat brain synaptosomesBiochemical Pharmacology, 1974
- Bromocriptine in ParkinsonismBMJ, 1974
- Effect of nomifensine on motor activity, dopamine turnover rate and cyclic 3?, 5?-adenosine monophosphate concentrations of rat striatumNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1974
- 8-Amino-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline, a new antidepressant.1973